Nivolumab is a fully human monoclonal IgG4 antibody that is approved by the U.S. Food and Drug Administration for the trea™ent of bladder cancer. It binds to the programmed cell death protein 1 (PD-1) on the surface of activated T cells. Nivolumab functions as PD-1 inhibitor for targeted immunotherapy. GenScript MonoRab™ Anti-Nivolumab Antibody (47F6), mAb, Rabbit is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a rabbit immunized with Nivolumab.